RVNC(Delisted)
Revance TherapeuticsยทNASDAQ
--
--(--)
RVNC Profile
Revance Therapeutics, Inc.
A commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings
1222 Demonbreun Street, Suite 2000, Nashville, Tennessee, 37203
--
Revance Therapeutics, Inc., a Delaware corporation, was founded on August 10, 1999 as Essentia Biosystems, Inc. The company is a professional clinical-stage biopharmaceutical company focused on the development, manufacture and commercialization of abnormal-type botulinum toxin products for beauty and treatment. Botulinum toxin is a good protein that is widely used in cosmetic and therapeutic indications and is a multi-billion dollar market in the United States and other countries. Currently approved and commercially available botulinum toxin is an injection type. RT001, the company's main product candidate, is a topical formulation of botulinum toxin type a, which is considered to have significant advantages over existing injectable botulinum toxin market products. The Company's second product candidate, RT002, is a new formulation of the botulinum toxin type for injection, which is designed to be more targeted and longer-lasting compared to other botulinum toxin injection products. These product candidates combine the company's purified botulinum toxin and proprietary peptide delivery systems. The company has worldwide distribution rights for its two product candidates.
